[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study-Reference-Cited by-同舟云学术

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

Published:2024-06 Issue:10446 Volume:403 Page:2807-2817
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Singh Simron,Halperin Daniel,Myrehaug Sten,Herrmann Ken,Pavel Marianne,Kunz Pamela L,Chasen Beth,Tafuto Salvatore,Lastoria Secondo,Capdevila Jaume,García-Burillo Amparo,Oh Do-Youn,Yoo Changhoon,Halfdanarson Thorvardur R,Falk Stephen,Folitar Ilya,Zhang Yufen,Aimone Paola,de Herder Wouter W,Ferone Diego

Publisher

Elsevier BV

Reference27 articles.

1. Radiopharmaceutical therapy in cancer: clinical advances and challenges;Sgouros;Nat Rev Drug Discov,2020

2. [177Lu-DOTA0, Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy;de Jong;Int J Cancer,2001

3. Illuminating somatostatin analog action at neuroendocrine tumor receptors;Reubi;Trends Pharmacol Sci,2013

4. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors;Strosberg;N Engl J Med,2017

5. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial;Strosberg;Lancet Oncol,2021

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PRRT in high‐grade digestive neuroendocrine neoplasms (NET G3 and NEC);Journal of Neuroendocrinology;2024-09-07

2. Comparative analysis of international guidelines on the management of advanced non-functioning well-differentiated pancreatic neuroendocrine tumors;Cancer Treatment Reviews;2024-09

3. Neoadjuvant therapy with peptide receptor radionuclide therapy for pancreatic neuroendocrine tumours;British Journal of Surgery;2024-08-30

4. Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors;Cancers;2024-08-28

5. 177Lu-DOTATATE significantly extends PFS in patients with GEP-NETs, regardless of grade or origin;Medicom Conference Report ESMO GI 2024;2024-08-21